World Evidence, Pricing and Access Congress USA
World Evidence, Pricing and Access Congress USA takes place on 14–15 September 2027 at Hynes Convention Center, Boston. It is organised by Terrapinn, and B2DB lists 72 speakers and 16 sessions announced so far.
The World Evidence, Pricing and Access Congress USA is a congress on market access, pricing and evidence, held at the Hynes Convention Center in Boston, with main congress days on 14-15 September 2027 and pre-congress workshops on 13 September. It brings together pharma and biotech companies, payers, PBMs and government bodies across six tracks, with an exhibition, poster zone and one-to-one networking. It is the US edition of the World EPA Congress, which is held in Amsterdam.
Key facts
| Dates | 14–15 September 2027 (upcoming) |
|---|---|
| Venue | Hynes Convention Center, Boston, United States of America |
| Organiser | Terrapinn |
| Series | World Evidence, Pricing and Access Congress USA |
| Speakers | 72 |
| Sessions | 16 |
| Stages | Keynotes, HEOR and RWE, Patient Access and Services, Specialty Pharmacy, Artificial Intelligence, Market Access and Commericalization, Policy and Reform |
| Official site | terrapinn.com/conference/world-evidence-pricing-access-congress-us/agenda.stm |
Keynote speakers
- Ipek Ozer Stillman Head, Global Health Economics, Payer Value & Patient Access, Takeda
- Charles Makin Head of RWE, Boehringer Ingelheim
- Divya Iyer Senior Vice President and Head of Revenue for Pharma Direct, GoodRx
- George Van Antwerp SVP, Product Innovation and Strategic Planning, Prime Therapeutics
- Rujul Desai Senior Counselor to the Administrator, CMS
- Jenny Goins Chief of Staff, National Alliance of Healthcare Purchaser Coalitions
- Sean Dickson Senior Vice President, Pharmaceutical Policy and Strategy, AHIP
- AJ Loiacono CEO, Judi Health
- Ellie Adair Chief Operating Officer, ICER
Who is speaking at World Evidence, Pricing and Access Congress USA?
72 speakers. Compiled from the published agenda; speakers can claim and verify their own entry.
- Ipek Ozer Stillman Head, Global Health Economics, Payer Value & Patient Access, Takeda
- Charles Makin Head of RWE, Boehringer Ingelheim
- Divya Iyer Senior Vice President and Head of Revenue for Pharma Direct, GoodRx
- George Van Antwerp SVP, Product Innovation and Strategic Planning, Prime Therapeutics
- Rujul Desai Senior Counselor to the Administrator, CMS
- Jenny Goins Chief of Staff, National Alliance of Healthcare Purchaser Coalitions
- Sean Dickson Senior Vice President, Pharmaceutical Policy and Strategy, AHIP
- AJ Loiacono CEO, Judi Health
- Ellie Adair Chief Operating Officer, ICER
- Jorge Arellano Senior Vice President, Global Head PAVE, Pricing, Access, Value & Evidence, BioMarin
- Brian Reid Principal, Reid Strategic
- Devika Gupta Head of Value for Healthcare Systems & Economics, Sanofi
- Daisuke Goto Director, Medical Affairs and Outcomes Research, Organon Inc.
- Gillian Stynes Executive Director, Global Market Access & Pricing, Merck
- Mike Baldzicki Vice President Specialty Pharmacy Biopharma Access & Growth, Walgreens
- Alexander Natz Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
- Jag Chhatwal Director, Center for Health Technology Assessment, Harvard Medical School
- Niall Brennan Chief Data & Analytics Officer, Horizon Blue Cross Blue Shield of New Jersey
- Alan Balch Executive Chair, Patient Advocate Foundation
- Siguroli Teitsson Senior Director, Global HEOR, Bristol Myers Squibb
- Melanie Lendnal Executive Vice President, Chief of Advocacy, The ALS Association
- William Shrank Chief Executive Officer, Aradigm
- Annette Powers Global Senior VP, Value Access & Public Policy, Astellas
- Susan Dentzer President and Chief Executive Officer, America's Physician Groups
- Chris Mancill Board Member, AstraZeneca
- Saira Jan Vice President and Chief Pharmacy Officer, Horizon Blue Cross Blue Shield of New Jersey
- Christopher Hatwig President, Apexus LLC
- Robert Popovian Founder, Conquest Advisors
- Jocelyn Ulrich Vice President, Policy & Research, PhRMA
- Aleata Postell Senior Vice President Pharmacy Business Development, Humana
- Dilip Patel SVP Global Pricing and Market Access, Autolus
- Walmon Leal Vice President, Head of Global Pricing Tenders & Contract, Viatris
- Katy Lees Director of 340B Policy and Business Strategy, University of Rochester School of Medicine and Dentistry
- Kimberly Lenz Chief Pharmacy Officer, MassHealth
- Linsey Krueger Healthcare Executive, Prime Therapeutics
- Kevyn Adler Senior Director, Market Access Product & Pipeline Strategy, Regeneron
- Paul Schiferl 340B Consultant, Pharmacist, Citizens Health
- Sheela Upadhyaya Rare Disease Consultant, Rarely Ordinary
- Christoph Glaetzer Chief Global Value and Access Officer, Johnson & Johnson Innovative Medicine
- Sven Klijn Director, HEOR Evidence Acceleration & Innovation, Bristol Myers Squibb
- Katheryne Richardson Chief Strategy Officer, Second Sight Solutions
- Patricia Dorling Senior Director, HEOR, Gene Therapy, Insmed
- Sean Sullivan Professor, The CHOICE Institute School of Pharmacy
- Riad Dirani Vice President, Global Health Economics and Outcomes Research, Teva Pharmaceuticals
- Alex Bastian Vice President, Commercial Strategy, Memo Therapeutics AG
- Antonio Ciaccia Chief Executive Officer, 46brooklyn Research
- Bill Malcolm Executive Director, Global HEOR EAI, Bristol Myers Squibb
- Sue Peschin President & CEO, Alliance for Aging Research
- Jay Weaver Vice President Payor Relations, PANTHERx Rare Pharmacy
- Marcus Droege EVP, Managing Partner, Pharmaconcepts Inc.
- Sonia Tadjalli Vice President & US Head, Biosimilars and Specialty, Sandoz Group AG
- Sonit Handa Founder & Principal, Biopharma Strategy and Operations, Biovance Consulting
- Andrew Spiegel Chief Executive Officer, Global Colon Cancer Association
- Kirsten Axelsen Independent Consultant, Grasshopper Industries
- Sheila Arquette President & CEO, National Association of Specialty Pharmacy (NASP)
- Ed Schoonveld Advisor and Coach, Schoonveld Advisory, LLC
- Heather Staples Executive Vice President, EBTS & Operations & CIO, Horizon Blue Cross Blue Shield of New Jersey
- Scott Mcgoohan Executive Director, Public Policy & Reimbursement, Vertex Pharmaceuticals
- Gergana Zlateva VP, Value & Access Strategy Business Unit Lead, Oncology, Patient & Health Impact, Pfizer Inc.
- Vanessa Mirsky Vice President, Life Sciences Data Strategy, RWE/RWD, OneOncology
- Edmund Pezalla CEO, Enlightenment Bioconsult, LLC
- Alexander Pham Executive Director, Strategy and Business Development, Boston Medical Center (BMC)
- Sabrina Aery Founder and Principal, Aery Policy and Access Partners, LLC
- Melissa Majerol Associate Director, Oncology Policy Strategy, AstraZeneca
- Andrew York Executive Director, Maryland Prescription Drug Affordability Board
- Brittany La Couture Vice President of Health Policy, Applied Policy
- Tonya Winders President, gaapp.org
- Bilal Saiyad Associate Director, Field Medical Systems Lead – Operations, Analytics, and Innovation, Biogen Inc.
- Christine Gilroy Consultant, Gilroy and Associates
- Joey Mattingly Vice Chair of Research - College of Pharmacy, Associate Professor - Pharmacotherapy, University of Utah
- R. Brett McQueen Associate Professor, University of Colorado
- Ulrich Neumann Director, J&J Center for US Healthcare Policy Research
Most represented companies
- Horizon Blue Cross Blue Shield of New Jersey — 3 speakers
- AstraZeneca — 2 speakers
- Bristol Myers Squibb — 2 speakers
- Prime Therapeutics — 2 speakers
What's on the agenda at World Evidence, Pricing and Access Congress USA?
16 sessions.
Day 1 — Tuesday 14 September 2027
- Opening Keynote Panel: PBM Reform, Transparency, and the Future of the Purchaser-Payer Relationship 09:00 · Keynotes — George Van Antwerp, Rujul Desai, Jenny Goins, AJ Loiacono
- MFN and US Pricing Policy: Preparing for the Upcoming US Legislative Shifts and Their Impact on Global and Long-Term Pricing Strategy 10:00 · Keynotes — Jorge Arellano, Annette Powers, Robert Popovian, Christoph Glaetzer +1 more
- Bridging the US Payer Trust with Robust Real-World Evidence 15:10 · HEOR and RWE — Charles Makin, Devika Gupta, Niall Brennan, Kimberly Lenz +1 more
- Global Interplay Between US And Ex-US Market Dynamics 15:10 · Patient Access and Services — Alexander Natz, Dilip Patel
- Affording The Unaffordable: Solutions For Financing High-Cost Curative Therapies 15:10 · Specialty Pharmacy — Melanie Lendnal, Susan Dentzer
- AI and Market Access: Utilizing Clinical and Economic Evidence In Reimbursement Discussions 15:10 · Artificial Intelligence — Daisuke Goto, Jag Chhatwal, Sven Klijn
- Next Generation Launch Sequencing Strategies: How to Succeed in an Increasingly Volatile Global Climate 15:10 · Market Access and Commericalization — Gillian Stynes, Walmon Leal, Kevyn Adler
- Reforming 340B: What Can Be Done to Regain Program Integrity? 15:10 · Policy and Reform — Brian Reid, Christopher Hatwig, Katy Lees, Paul Schiferl
Day 2 — Wednesday 15 September 2027
- Keynote Opening Panel: A Vision for Transparent, Value-Aligned Launch Pricing in 2027 and Beyond 09:00 · Keynotes — Ipek Ozer Stillman, Charles Makin, Divya Iyer, Sean Dickson +1 more
- The Modernization of Specialty Pharmacy: How Have the Roles of Key Stakeholders Shifted in the Access Journey? 10:00 · Keynotes — Mike Baldzicki, William Shrank, Annette Powers, Chris Mancill +3 more
- Shielding Rare Disease & Orphan Drugs from MFN and Global Price Compression 15:10 · Policy and Reform — Sheela Upadhyaya
- The AI Arms Race: Navigating The Automation Of Processes Across All Stakeholders In The Healthcare Industry 15:10 · Artificial Intelligence — Niall Brennan, Siguroli Teitsson
- The Direct-To -Consumer Model: The New Commercial Architecture? 15:10 · Market Access and Commericalization — Divya Iyer
- Two years on from the First Wave of MFP-Priced Drugs: What Have We Learnt? 15:10 · Patient Access and Services — Jocelyn Ulrich, Katheryne Richardson
- Rethinking Trial Design for Market Access: Aligning R&D With HTA And IRA Demands For Strong Post Market Outcomes 15:10 · HEOR and RWE — Ipek Ozer Stillman, Alan Balch
- Delivering Patient Centric Outcomes At Scale: Solving The Specialty Access Crisis 15:10 · Specialty Pharmacy — Saira Jan
Who is organising and sponsoring World Evidence, Pricing and Access Congress USA?
Organiser (1)
Supporting Partners (4)
BioPartner U.K. Ltd · Biopharma Asia · PharmaVision · Market Access Today
Source: the published agenda. See how B2DB compiles its records.